AIM AT MELANOMA

AIM AT MELANOMA (AIM) IS GLOBALLY ENGAGED AND LOCALLY INVESTED IN ADVANCING THE BATTLE AGAINST MELANOMA THROUGH INNOVATIVE RESEARCH, LEGISLATIVE REFORM, EDUCATION, AND PATIENT AND CAREGIVER SUPPORT. FOUNDED IN 2004, AIM AT MELANOMA IS THE LARGEST INTERNATIONAL MELANOMA FOUNDATION SEEKING THE CURE FOR MELANOMA. AIM BELIEVES THAT THE CURE FOR MELANOMA WILL BE FOUND MORE QUICKLY BY BRINGING TOGETHER LEADING GLOBAL RESEARCHERS AND FUNDING THEIR COLLABORATIVE RESEARCH. OUR THREE PARADIGM-SHIFTING GLOBAL RESEARCH INITIATIVES, INCLUDING THE MELANOMA TISSUE BANK CONSORTIUM, ARE POISED TO RESHAPE THE FUTURE OF MELANOMA. AIM IS THE RESPECTED VOICE OF MELANOMA ACROSS THE NATION. WHEN DRUGS ARE APPROVED, LEGISLATION IS DRAFTED, AND RESEARCH IS ASSESSED, AIM IS AT THE TABLE, SPEAKING LOUDLY AND CLEARLY ON BEHALF OF PATIENTS AND THEIR FAMILIES. AIM IS THE TRUSTED ADVISOR FOR PHARMACEUTICAL COMPANIES, MEDICAL BOARDS, AND GOVERNMENT AGENCIES ON CRITICAL TOPICS THAT AFFECT MELANOMA PATIENTS.